Background: HIV-related stigma is associated with increased risk-taking behavior, reduced uptake of HIV testing, and decreased adherence to antiretroviral therapy (ART).
Author Archives: JAIDS
Objective: Combination antiretroviral therapy (ART) decreases the risk of sexual HIV transmission by suppressing blood and genital HIV RNA concentrations.
Background: Tuberculosis (TB) risk and mortality increase in the 6 months after highly active antiretroviral therapy (HAART) initiation.
Introduction: Treatment as prevention relies on early uptake of HIV treatment, but onward transmission during primary HIV infection may be affected by changes in sexual risk behavior after diagnosis.
Objectives: To estimate the number of persons living with HIV (PLWH) in the United States and to describe their care status.
Introduction: This study prospectively examined whether HIV leads to elevated risk for intimate partner violence (IPV) for women and how this risk varies depending on HIV status disclosure to a partner.
Abstract: Pill counts with calculated adherence percentages are used in many settings to monitor adherence, but can be undermined by patients discarding pills to hide nonadherence.
Background: The uptake of intensified active TB case-finding among HIV-infected patients using symptom screening is not well understood.
Objectives: To perform geriatric assessments in older HIV-infected adults in San Francisco and examine the association with age and the Veterans Aging Cohort Study (VACS) index scores.
Context: Smoking is responsible for increased morbidity and mortality in HIV-infected smokers.
Objective: To evaluate the quantification performance of the new Cepheid GeneXpert HIV-1 viral load assay, on a wide panel of HIV-1 variants.
Background: FRAX is a validated, computer-based clinical fracture risk calculator that estimates the 10-year risk of major osteoporotic (clinical spine, forearm, hip, or shoulder) fracture, and hip fracture alone.
Background: We report the pharmacokinetic interactions of combined oral contraceptive (COC) containing ethinyl estradiol (EE2)/desogestrel (DSG) with lopinavir/ritonavir (LPV/r) in 16 HIV-positive adolescents.
Background: Quantifying tissue drug concentrations can yield important information during drug development, but complicates pharmacokinetic study design.